Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described new serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Levena Biopharma Co. Ltd. and Sorrento Therapeutics Inc. have synthesized antibody-drug conjugates consisting of auristatin analogues covalently linked to monoclonal antibody targeting B-cell maturation protein (BCMA) through a linker.
Kancera AB has shown that its Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer.
First Health Pharmaceuticals BV has presented oxadiazole derivatives acting as DEAD box RNA helicase (DDX) inhibitors reported to be useful for the treatment of cancer.
The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has identified new imidazo[1,2-a]pyrazines acting as serine/threonine-protein kinase haspin (GSG2) inhibitors reported to be useful for the treatment of cancer.
Shanghai Allygen Biologics Co. Ltd. has synthesized new antibody-drug conjugates (ADC) comprising antibodies targeting programmed cell death 1 ligand 1 (CD274; PD-L1) covalently linked to SN-38 through a linker and reported to be useful for the treatment of cancer.
Researchers have designed a 3D model of lung cancer that is composed of bronchial epithelial, fibroblasts, epithelial, lung adenocarcinoma and immune cells grown in different layers in a matrigel.
RSS
